These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36074798)

  • 1. Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study.
    Yu T; Cai QQ; Zhai QL; Li L; Fang X; Li J; Sun R; Yang H; Wang Z; Qian W; Xu-Monette ZY; Young KH; Yu L
    Leuk Lymphoma; 2022 Dec; 63(13):3082-3091. PubMed ID: 36074798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
    Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
    PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
    Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
    Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
    Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
    J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
    Zhang L; Dong YJ; Peng HL; Li H; Zhang MZ; Wang HH; Liu QH; Su LP; Zhong LY; Wu WJ; Huang L; Yan XJ; Fan L; Tang WJ; Li ZL; Bi LT; Li Y; Gao GX; Gao L; Liu TB; Wei YQ; Liu Y; Yu L; Zhou H; Sun CY; Qian WB; Zou DH; Zhang HL; Ding KY; Wang XB; Bai O; Huang WR; Chen B; Yang L; Song J; Gao D; Chen T; Luo J; Wang SY; Ma LM; Fajgenbaum DC; Li J;
    Lancet Reg Health West Pac; 2023 May; 34():100720. PubMed ID: 37283978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multicentric Castlemans disease. Symptoms, diagnostics and therapy].
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.
    Liu W; Cai Q; Yu T; Strati P; Hagemeister FB; Zhai Q; Zhang M; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Oksenhendler E; Xu-Monette ZY; Young KH; Yu L
    Am J Cancer Res; 2022; 12(9):4227-4240. PubMed ID: 36225639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital.
    González-García A; Patier de la Peña JL; García-Cosio M; Sarhane Y; Sánchez Díaz C; Barbolla Díaz I; López Rodríguez M; Moreno MÁ; Villarubia J; Manzano L
    Leuk Lymphoma; 2019 Dec; 60(14):3442-3448. PubMed ID: 31305183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The full spectrum of Castleman disease: 273 patients studied over 20 years.
    Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L
    Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of 65 patients with Castleman disease in a single center in China.
    Wang XQ; Zhong NN; Sun Q; Yan SC; Xu GC; Wang YG; Peng LW; Liu B; Bu LL
    Sci Rep; 2022 May; 12(1):8694. PubMed ID: 35610300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
    Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.
    Nagy A; Bhaduri A; Shahmarvand N; Shahryari J; Zehnder JL; Warnke RA; Mughal T; Ali S; Ohgami RS
    Blood Adv; 2018 Mar; 2(5):481-491. PubMed ID: 29496669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of Castleman Disease.
    Simpson D
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):1-10. PubMed ID: 29157611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.
    Yu L; Shi M; Cai Q; Strati P; Hagemeister F; Zhai Q; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Zhang L; Li J; Oksenhendler E; Xu-Monette ZY; Young KH
    Oncologist; 2020 Nov; 25(11):963-973. PubMed ID: 32852137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease.
    Horna P; King RL; Jevremovic D; Fajgenbaum DC; Dispenzieri A
    Haematologica; 2023 Jan; 108(1):207-218. PubMed ID: 35484648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients.
    Zhang X; Rao H; Xu X; Li Z; Liao B; Wu H; Li M; Tong X; Li J; Cai Q
    Cancer Sci; 2018 Jan; 109(1):199-206. PubMed ID: 29124835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
    van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
    Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
    Okamoto S
    Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in Castleman Disease.
    Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
    Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease.
    Qian S; Ding M; Hou H; Wang Z; Zhang J; Zhang Y; Dong M; Zhu L; Wang G; Li W; Zhang X
    Front Immunol; 2022; 13():899073. PubMed ID: 35655778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.